Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 247,663
  • Shares Outstanding, K 78,127
  • Annual Sales, $ 0 K
  • Annual Income, $ -168,390 K
  • EBIT $ -165 M
  • EBITDA $ -176 M
  • 60-Month Beta 0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.78

Options Overview Details

View History
  • Implied Volatility 149.09% (-82.89%)
  • Historical Volatility 49.62%
  • IV Percentile 23%
  • IV Rank 15.67%
  • IV High 593.81% on 05/16/25
  • IV Low 66.45% on 09/02/25
  • Expected Move (DTE 11) 0.92 (28.69%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,016
  • Open Int (30-Day) 1,055
  • Expected Range 2.28 to 4.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.53
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.87 +11.50%
on 11/13/25
3.50 -8.57%
on 11/12/25
-0.07 (-2.14%)
since 11/07/25
3-Month
2.78 +15.11%
on 10/02/25
3.50 -8.57%
on 11/12/25
-0.05 (-1.54%)
since 09/08/25
52-Week
2.45 +30.35%
on 05/15/25
4.02 -20.40%
on 07/28/25
+0.26 (+8.84%)
since 12/06/24

Most Recent Stories

More News
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV   Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...

AVIR : 3.20 (+0.95%)
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

AVIR : 3.20 (+0.95%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.37
2nd Resistance Point 3.30
1st Resistance Point 3.25
Last Price 3.20
1st Support Level 3.13
2nd Support Level 3.06
3rd Support Level 3.01

See More

52-Week High 4.02
Fibonacci 61.8% 3.42
Fibonacci 50% 3.24
Last Price 3.20
Fibonacci 38.2% 3.05
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar